Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine dispersible in infants under 5 kg with uncomplicated falciparum malaria
2011-005852-33Phase 2
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of artemether and lumefantrine in Malaria, sponsored by Novartis. Primary endpoint: PCR-corrected 28-day parasitological cure rate.
02
Drugs
artemetherlumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on 2011-005852-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005852-33.